Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI – Get Free Report) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 11,800 shares, a decrease of 41.6% from the September 30th total of 20,200 shares. Based on an average daily trading volume, of 36,900 shares, the short-interest ratio is presently 0.3 days.
Scinai Immunotherapeutics Stock Performance
Shares of Scinai Immunotherapeutics stock opened at $3.45 on Friday. The firm has a market cap of $1.60 million, a PE ratio of -0.01 and a beta of 2.47. The business’s 50 day simple moving average is $3.72 and its 200 day simple moving average is $3.90. Scinai Immunotherapeutics has a 52-week low of $2.23 and a 52-week high of $8.92.
Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) last posted its earnings results on Thursday, August 15th. The company reported ($3.57) EPS for the quarter. The company had revenue of $0.28 million for the quarter.
Scinai Immunotherapeutics Company Profile
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
Recommended Stories
- Five stocks we like better than Scinai Immunotherapeutics
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Why Invest in 5G? How to Invest in 5G Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What Are Some of the Best Large-Cap Stocks to Buy?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.